Genomes and Genes
ANNA LEENA SIREN
Affiliation: Max Planck Institute for Experimental Medicine
- Erythropoietin--a novel concept for neuroprotectionA L Siren
Max Planck Institute for Experimental Medicine, Goettingen, Germany
Eur Arch Psychiatry Clin Neurosci 251:179-84. 2001....
- Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotraumaA L Siren
Department of Psychiatry, Georg August University, and Max Planck Institute for Experimental Medicine, Goettingen, Germany
Neurochem Res 25:957-69. 2000..These changes seem to be posttranscriptional and cell type specific. They favor vasoconstriction increasing the risk of late vasospasm and ischemia...
- Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brainA L Siren
Max Planck Institute for Experimental Medicine, Hermann Rein Strasse 3, 37075 Gottingen, Germany
Acta Neuropathol 101:271-6. 2001....
- Proinflammatory cytokine expression contributes to brain injury provoked by chronic monocyte activationA L Siren
Department of Neurology, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
Mol Med 7:219-29. 2001..The effect of chronic monocyte activation on the development of cerebral infarcts was thus studied in rats after provocation of a modified local Swartzman reaction, in brain vasculature...
- Endothelin B receptor deficiency augments neuronal damage upon exposure to hypoxia-ischemia in vivoANNA LEENA SIREN
Department of Neurology, Georg August University, and Max Planck Institute for Experimental Medicine, Hermann Rein Strasse 3, D 37075 Gottingen, Germany
Brain Res 945:144-9. 2002..n=5, P=0.0560). To conclude, absence of functional ETB receptors is associated with an increased susceptibility to HI in-vivo, which is not intrinsic to neurons. Antagonism of ETB receptors seems not to be desirable in ischemic stroke...
- A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brainHannelore Ehrenreich
Max Planck Institute of Experimental Medicine, Georg August University, 37075 Goettingen, Germany
Proc Natl Acad Sci U S A 102:862-7. 2005..This effect is not only inhibited by EPO but also by neurotrophins. We suggest that the proapoptotic function of TPO helps to select for neurons that have acquired target-derived neurotrophic support...
- In vitro gender differences in neuronal survival on hypoxia and in 17beta-estradiol-mediated neuroprotectionAndrea Heyer
Max Planck Institute for Experimental Medicine, Gottingen, Germany
J Cereb Blood Flow Metab 25:427-30. 2005..Estrogens, acting via membrane receptors, had a higher neuroprotective power in male neurons, explained at least in part by the pronounced increase in estrogen receptor beta/alpha ratio during hypoxia in male cells only...
- Erythropoietin therapy for acute stroke is both safe and beneficialHannelore Ehrenreich
Max Planck Institute for Experimental Medicine, Departments of Neurology and Psychiatry, Georg August University, Goettingen, Germany
Mol Med 8:495-505. 2002..EPO protects neurons from hypoxic/ ischemic injury. The objective of this trial is to study the safety and efficacy of recombinant human EPO (rhEPO) for treatment of ischemic stroke in man...
- Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cellsJochen H Weishaupt
Department of Neurology, University of Gottingen, Gottingen, Germany
Invest Ophthalmol Vis Sci 45:1514-22. 2004....
- Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect?Christian Unzicker
Division of Clinical Neuroscience, Max Planck Institute for Experimental Medicine, Gottingen, Germany
Neurochem Res 30:1305-9. 2005..We suggest that CB1-receptor upregulation in the ETB-mutant hippocampus reflects an attempt to compensate for the lack of ETB-receptors...
- Erythropoietin: novel approaches to neuroprotection in human brain diseaseHannelore Ehrenreich
Clinical Neuroscience Laboratory, Max Planck Institute for Experimental Medicine, Gottingen, Germany
Metab Brain Dis 19:195-206. 2004....
- A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemiaHannelore Ehrenreich
Max Planck Institute for Experimental Medicine, Hermann Rein Str 3, 37075 Gottingen, Germany
Transfus Apher Sci 31:39-44. 2004..At the moment a multicenter study is being carried out in Germany...
- Reduced oxidative damage in ALS by high-dose enteral melatonin treatmentJochen H Weishaupt
Department of Neurology, Georg August University, Gottingen, Germany
J Pineal Res 41:313-23. 2006..This combination of preclinical effectiveness and proven safety in humans suggests that high-dose melatonin is suitable for clinical trials aimed at neuroprotection through antioxidation in ALS...
- Exploring recombinant human erythropoietin in chronic progressive multiple sclerosisHannelore Ehrenreich
Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Georg August University, Gottingen, Germany
Brain 130:2577-88. 2007..There were no adverse events, no safety concerns and a surprisingly low need of blood-lettings. This first pilot study demonstrates the necessity and feasibility of controlled trials using high-dose rhEPO in chronic progressive MS...
- Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root gangliaWolfgang Knabe
Department of Anatomy Embryology, Georg August University Gottingen, Kreuzbergring 36, 37075 Gottingen, Germany
Anat Embryol (Berl) 210:209-19. 2005....
- Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin systemChristiane Albert-Weißenberger
University Clinic of Würzburg, Department of Neurology, Wurzburg, Germany
Prog Neurobiol 101:65-82. 2013..Experimental findings are also compared with human data if available, and potential therapeutic implications are discussed...
- FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammationStine Mencl
Department of Neurology, University Hospital W rzburg, W rzburg, Germany
J Neuroimmunol 274:125-31. 2014..We conclude that pharmacological S1P receptor modulation is an unfavorable strategy to combat TBI. Moreover, our findings put into perspective the pathophysiological relevance of inflammatory cells in traumatic neurodegeneration...
- Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activationChristiane Albert-Weissenberger
Department of Neurology, University Clinic of Würzburg, Wurzburg, Germany
J Cereb Blood Flow Metab 32:1747-56. 2012..Inhibition of B1R may become a novel strategy to counteract trauma-induced neurodegeneration...
- Characterization of binding kinetics of [3H]Tyr-D-Arg2-Phe-Sar4 at opioid receptorsStefan Vonhof
Department of Cardiology and Pneumology, Georg August University, Robert Koch Str 40, 37075 Gottingen, Germany
Eur J Pharmacol 473:127-34. 2003..Thus, [3H]TAPS, depending on the presence of divalent cations, serves as ligand at two MOP receptor binding sites in the calf thalamus, which may represent distinct affinity states of the same receptor or receptor subtypes thereof...